PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31773789-6 2020 In addition, the proportion of T-helper (Th)1 and Th17 cells in dermal and splenic cells of IMQ-treated mice were decreased by application of NG-anti-miR-210, accompanied by decreased interleukin-17A and gamma-interferon mRNA levels. Imiquimod 92-95 interleukin 17A Mus musculus 184-199 31982823-0 2020 Bruton"s tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells. Imiquimod 46-55 interleukin 17A Mus musculus 128-134 31288049-10 2019 CONCLUSION: WBR is effective in the imiquimod-induced psoriasis-like inflammation mouse model with the efficacy arising from its proliferation inhibition of Th1/Th17 cells and epidermal keratinocytes via the down-regulation of the relevant inflammatory cytokines such as IL-23, IL-17A, and IL-17F. Imiquimod 36-45 interleukin 17A Mus musculus 278-284 31659208-9 2019 These results indicated that MHP1-AcN could decrease imiquimod-induced IL-6, IL-23 and IL-17A production. Imiquimod 53-62 interleukin 17A Mus musculus 87-93 31407330-12 2019 Kaempferol also lowered the percentage of IL-17A+ CD4+ T cells in the spleen and lymph nodes of IMQ-induced psoriatic mice. Imiquimod 96-99 interleukin 17A Mus musculus 42-48 31362906-0 2019 Anti-IL-17A and IL-23p19 antibodies but not anti-TNFalpha antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis. Imiquimod 155-164 interleukin 17A Mus musculus 5-11 31362906-10 2019 Anti-IL-17A or IL-23p19 antibody-induced Tregs significantly increased the number of Foxp3+ cells and IL-10 expression in imiquimod-induced psoriasiform dermatitis in recipient mice but anti-TNFalpha antibody-induced Tregs did not. Imiquimod 122-131 interleukin 17A Mus musculus 5-11 31362906-11 2019 CONCLUSION: Anti-IL-17A or IL-23p19 antibody inhibits the IL-17/IL-23 signaling pathway, and induces expansion of Tregs and their suppressive capacity in imiquimod-induced psoriasiform dermatitis. Imiquimod 154-163 interleukin 17A Mus musculus 17-23 31362906-11 2019 CONCLUSION: Anti-IL-17A or IL-23p19 antibody inhibits the IL-17/IL-23 signaling pathway, and induces expansion of Tregs and their suppressive capacity in imiquimod-induced psoriasiform dermatitis. Imiquimod 154-163 interleukin 17A Mus musculus 17-22 31362906-8 2019 Anti-IL-17A or IL-23p19 antibody-treated imiquimod-applied mice showed a significant increase in the number of Foxp3+ IL-10+ Tregs. Imiquimod 41-50 interleukin 17A Mus musculus 5-11 30834454-4 2019 Both topical ceramidase and sphingosine kinase 1/2 inhibition, which blocks S1P generation, alleviated imiquimod-induced skin lesions and reduced the serum interleukin 17-A levels induced by application of imiquimod. Imiquimod 206-215 interleukin 17A Mus musculus 156-172 30615272-3 2019 Intradermal injections of IL-23 and topical application of Aldara/IMQ induce skin inflammation in mice with features similar to psoriasis-including epidermal hyperplasia and accumulation of inflammatory cells in epidermis and dermis-which is mediated by IL-17A, IL-22, and other factors implicated in the human disease. Imiquimod 59-65 interleukin 17A Mus musculus 254-260 30615272-3 2019 Intradermal injections of IL-23 and topical application of Aldara/IMQ induce skin inflammation in mice with features similar to psoriasis-including epidermal hyperplasia and accumulation of inflammatory cells in epidermis and dermis-which is mediated by IL-17A, IL-22, and other factors implicated in the human disease. Imiquimod 66-69 interleukin 17A Mus musculus 254-260 30481683-0 2019 ERK inhibitor JSI287 alleviates imiquimod-induced mice skin lesions by ERK/IL-17 signaling pathway. Imiquimod 32-41 interleukin 17A Mus musculus 75-80 30684554-0 2019 Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes. Imiquimod 0-9 interleukin 17A Mus musculus 51-56 31024570-3 2019 This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression. Imiquimod 141-150 interleukin 17A Mus musculus 204-210 31024570-3 2019 This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression. Imiquimod 152-155 interleukin 17A Mus musculus 204-210 30743203-5 2019 It was found that genistein can significantly improve IMQ-induced pathological scores of cutaneous skin lesions in mice, reduce epidermal thickness, and inhibit the expression of inflammatory factors,including interleukin (IL)-1beta, IL-6, tumour necrosis factor-alpha (TNF-alpha), chemokine ligand 2 (CCL2), IL-17 and IL-23. Imiquimod 54-57 interleukin 17A Mus musculus 309-314 30481683-6 2019 In this study, a small synthetic molecule JSI287 was found with the function of alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway during the screening of small molecule databases targeting ERK. Imiquimod 92-95 interleukin 17A Mus musculus 134-139 30372845-8 2018 We conclude that DTF alleviates IMQ-induced psoriasis by attenuating inflammatory cascades, reducing keratinocytes proliferation and improving epidermal barrier function through suppressing TNF-alpha and IL-17 A signal pathways. Imiquimod 32-35 interleukin 17A Mus musculus 204-211 29763944-8 2018 Baicalin also inhibited imiquimod-induced interleukin-17A production in skin draining lymph node cells. Imiquimod 24-33 interleukin 17A Mus musculus 42-57 29225340-5 2018 First, an attenuated form of imiquimod-induced psoriasis-like skin inflammation was demonstrated in CD6-deficient mice, as deduced from lower epidermal thickness and local reduced production of pro-inflammatory cytokines, namely, interleukin-17A. Imiquimod 29-38 interleukin 17A Mus musculus 230-245 29867905-7 2018 Further, mRNA expression analysis indicated a significant increase in gene expression levels of pro-inflammatory cytokines, including IL-19, IL-17A, and IL-23 in IMQ and IMQ plus vaseline treated groups than that of the control. Imiquimod 162-165 interleukin 17A Mus musculus 141-147 30064075-0 2018 Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing gammadelta T cells. Imiquimod 22-31 interleukin 17A Mus musculus 125-131 30064075-12 2018 CONCLUSION: Indirubin alleviates IMQ-induced psoriasis-like dermatitis mainly through reducing the inflammatory responses mediated by IL-17 A-producing gammadelta T cells involving Jak3/Stat3 activation. Imiquimod 33-36 interleukin 17A Mus musculus 134-141 29959474-11 2018 Gut Th17 cells induced by anti-CD3 express IL-17A and F together as skin gammadelta T cells of IMQ-treated mice. Imiquimod 95-98 interleukin 17A Mus musculus 43-49 29867905-7 2018 Further, mRNA expression analysis indicated a significant increase in gene expression levels of pro-inflammatory cytokines, including IL-19, IL-17A, and IL-23 in IMQ and IMQ plus vaseline treated groups than that of the control. Imiquimod 170-173 interleukin 17A Mus musculus 141-147 29247486-6 2018 IL-17A mRNA expression was significantly increased in the skin of IMQ-treated HFD mice; the expression of IL-22, IL-23 and TNF-alpha mRNA was not enhanced. Imiquimod 66-69 interleukin 17A Mus musculus 0-6 29155016-0 2018 Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-alpha/IFN-gamma-induced inflammatory response in keratinocytes and T cell-derived IL-17. Imiquimod 64-73 interleukin 17A Mus musculus 223-228 29535261-2 2018 In a mouse model of imiquimod-induced psoriasiform skin inflammation, we found that p38alpha activity in Langerhans cells (LCs), a skin-resident subset of DCs, promoted the generation of T cells that produce IL-17, a proinflammatory cytokine that is implicated in autoimmune disease. Imiquimod 20-29 interleukin 17A Mus musculus 208-213 29523162-11 2018 The increased expression of splenic Th17 cell percentage, along with Notch1, Hes-1, RORgammat and IL-17A mRNA and IL-17A serum concentration in IMQ-treated mice were significantly decreased when experimental mice were treated by IMQ and DAPT combinedly. Imiquimod 144-147 interleukin 17A Mus musculus 98-104 29523162-11 2018 The increased expression of splenic Th17 cell percentage, along with Notch1, Hes-1, RORgammat and IL-17A mRNA and IL-17A serum concentration in IMQ-treated mice were significantly decreased when experimental mice were treated by IMQ and DAPT combinedly. Imiquimod 144-147 interleukin 17A Mus musculus 114-120 29523162-11 2018 The increased expression of splenic Th17 cell percentage, along with Notch1, Hes-1, RORgammat and IL-17A mRNA and IL-17A serum concentration in IMQ-treated mice were significantly decreased when experimental mice were treated by IMQ and DAPT combinedly. Imiquimod 229-232 interleukin 17A Mus musculus 98-104 29523162-11 2018 The increased expression of splenic Th17 cell percentage, along with Notch1, Hes-1, RORgammat and IL-17A mRNA and IL-17A serum concentration in IMQ-treated mice were significantly decreased when experimental mice were treated by IMQ and DAPT combinedly. Imiquimod 229-232 interleukin 17A Mus musculus 114-120 29523162-12 2018 Data obtained from in vitro study in IMQ-treated mice also demonstrated that blocking Notch1 signaling by DAPT can result in a dose-dependent decrease of Th17 cell proportion, mRNA expression of Notch1, Hes-1, RORgammat and IL-17A as well as IL-17A secretion in splenic CD4+ T cells. Imiquimod 37-40 interleukin 17A Mus musculus 224-230 29523162-12 2018 Data obtained from in vitro study in IMQ-treated mice also demonstrated that blocking Notch1 signaling by DAPT can result in a dose-dependent decrease of Th17 cell proportion, mRNA expression of Notch1, Hes-1, RORgammat and IL-17A as well as IL-17A secretion in splenic CD4+ T cells. Imiquimod 37-40 interleukin 17A Mus musculus 242-248 29247486-7 2018 Caspase-1 and IL-1beta were activated in the skin of IMQ-treated HFD mice, and their serum level of IL-17A, TNF-alpha and IL-1beta was significantly upregulated. Imiquimod 53-56 interleukin 17A Mus musculus 100-106 28677206-9 2018 IL-10 deficient mice also showed significantly higher serum levels of imiquimod-induced IL-17A and tumor necrosis factor-alpha by enzyme-linked immunosorbent assay on day 15. Imiquimod 70-79 interleukin 17A Mus musculus 88-126 27592361-5 2016 Subsequent analyses revealed that the production of Th17 cytokines (IL-17A and IL-23) in the serum and skin of IMQ-induced mice was significantly inhibited by agonistic anti-4-1BB Abs (10mg/kg), although Th1 cytokines (TNF-alpha and IFN-gamma) were not. Imiquimod 111-114 interleukin 17A Mus musculus 68-74 29150564-6 2018 Instead, a bone marrow chimera study suggested that CARD14 in radio-sensitive hematopoietic cells was required for IMQ-induced psoriasiform skin inflammation, controlling the number of Vgamma4+ T cells producing IL-17 or IL-22 infiltrating through the dermis to the inflamed epidermis. Imiquimod 115-118 interleukin 17A Mus musculus 212-217 28600817-9 2017 Additionally, studies in the imiquimod-induced psoriasis-like mouse model revealed that ACDs in psoriasis are IL17A-dependent. Imiquimod 29-38 interleukin 17A Mus musculus 110-115 27964879-6 2017 RESULTS: The severity of IMQ-induced dermatitis in langerin-DTA mice was significantly lower than that of wild-type mice, as evidenced by decreased level of ear thickness, inflammatory cell infiltration (gammadelta T cells and neutrophils) and inflammatory cytokine expression (IL-17, IL-22, IL-23 and tumor necrosis factor-alpha). Imiquimod 25-28 interleukin 17A Mus musculus 278-283 27540765-0 2016 MAD ointment ameliorates Imiquimod-induced psoriasiform dermatitis by inhibiting the IL-23/IL-17 axis in mice. Imiquimod 25-34 interleukin 17A Mus musculus 91-96 28963556-6 2017 IL-17A neutralization increased the expressions of iNOS and phospho-STAT1 in the IMQ-treated skin, but it decreased the expressions of CD206 and phospho-STAT3 proteins in the skin of Flg ft mice, suggesting that macrophages to change from the M2 to the M1 state in the skin of these mice. Imiquimod 81-84 interleukin 17A Mus musculus 0-6 28570931-12 2017 Furthermore, anti-IL17A antibody also led to a reduction in imiquimod-induced depression-like symptoms, as well as NFkappaB/p38MAPK signaling. Imiquimod 60-69 interleukin 17A Mus musculus 18-23 27773660-9 2017 Treatment with IL-17A further aggravated, whereas treatment with anti-IL17A antibody ameliorated IMQ-induced changes in hepatic injury/inflammation and protein/lipid metabolism. Imiquimod 97-100 interleukin 17A Mus musculus 70-75 27939414-14 2017 Also administration of IL-27 decreased IL-17A level while IL-27p28 antagonist increased IL-17A level in serum and psoriasis-like lesion in the IMQ-treated mice. Imiquimod 143-146 interleukin 17A Mus musculus 88-94 26614407-6 2016 At the molecular level, we demonstrated that the Aldara-induced mRNA expression of the psoriasis-related inflammatory markers interleukin (IL)-17C, IL-23p19, IL-12p40, IL-17A, IL-22 and S100A8 was significantly decreased in TNF-alpha KO mice compared with WT mice. Imiquimod 49-55 interleukin 17A Mus musculus 168-174 27221314-10 2016 In conclusion, these data demonstrate that Th2-type CHS exacerbated the IMQ-treated psoriatic inflammation of mice via the IL-23/IL-17 axis. Imiquimod 72-75 interleukin 17A Mus musculus 129-134 26048148-6 2015 Three-fold increases in the percentage of IL-17A(+) GDL T cells were observed in skin cell suspensions derived from IMQ-treated PD-1KO mice (versus WT controls), suggesting that the lack of PD-1 has a functional effect not only on alphabeta T cells, but also on GDL T cells, and that PD-1 may play a regulatory role in PsD. Imiquimod 116-119 interleukin 17A Mus musculus 42-48 26332438-4 2015 IL-17A/F-producing Vgamma4(+) Vdelta4(+) T cells populate and persist in the dermis for long periods of time after initial stimulation with Aldara. Imiquimod 140-146 interleukin 17A Mus musculus 0-6 26784569-6 2016 Administration of astilbin ameliorated IMQ-induced keratinocyte proliferation, infiltration of CD3+ cells to psoriatic lesions and ameliorated elevations in circulating CD4+ and CD8+ T cells and inflammatory cytokines (IL-17A, TNF-alpha, IL-6, IFN-gamma and IL-2). Imiquimod 39-42 interleukin 17A Mus musculus 219-225 26149470-0 2015 Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation. Imiquimod 0-9 interleukin 17A Mus musculus 115-121 24824846-1 2014 Accumulating evidence has shown that the Toll-like receptor 7 agonist imiquimod (IMQ) induces psoriasiform skin inflammation in mice and that this inflammation is dependent on the IL-23/IL-17 axis. Imiquimod 70-79 interleukin 17A Mus musculus 186-191 25777289-6 2015 When compared to imiquimod-treated control mice, imiquimod-treated obese mice expressed higher levels of psoriasis mediators, interleukin-17A (IL-17A) and IL-22 in the skin. Imiquimod 49-58 interleukin 17A Mus musculus 126-141 25777289-6 2015 When compared to imiquimod-treated control mice, imiquimod-treated obese mice expressed higher levels of psoriasis mediators, interleukin-17A (IL-17A) and IL-22 in the skin. Imiquimod 49-58 interleukin 17A Mus musculus 143-149 24824846-0 2014 Skin-penetrating methotrexate alleviates imiquimod-induced psoriasiform dermatitis via decreasing IL-17-producing gamma delta T cells. Imiquimod 41-50 interleukin 17A Mus musculus 98-103 24824846-1 2014 Accumulating evidence has shown that the Toll-like receptor 7 agonist imiquimod (IMQ) induces psoriasiform skin inflammation in mice and that this inflammation is dependent on the IL-23/IL-17 axis. Imiquimod 81-84 interleukin 17A Mus musculus 186-191 24569709-0 2014 IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing gammadelta T cells. Imiquimod 63-72 interleukin 17A Mus musculus 123-129 24569709-8 2014 Moreover, the IMQ-treated skin of LC-depleted mice showed a decreased number of IL-17A-producing CCR6+ gammadelta T cells. Imiquimod 14-17 interleukin 17A Mus musculus 80-86 24286371-2 2014 In this study, we report the effects of topical calcipotriol, camptothecin, clobetasol and tazarotene on the treatment of imiquimod (IMQ)-induced psoriasis-like inflammation, the development of which is dependent on the IL-23/IL-17A axis. Imiquimod 122-131 interleukin 17A Mus musculus 226-232 24718773-0 2014 Endogenous n-3 polyunsaturated fatty acids protect against imiquimod-induced psoriasis-like inflammation via the IL-17/IL-23 axis. Imiquimod 59-68 interleukin 17A Mus musculus 113-124 24387343-2 2014 In a mouse model of IMQ-induced psoriasis-like skin inflammation, T-helper (Th)17 cells and interleukin (IL)-17/IL-22-producing gammadelta-T cells have been shown to play a pivotal role. Imiquimod 20-23 interleukin 17A Mus musculus 92-111 23024273-3 2012 We found that mice lacking functional PI3Kdelta or PI3Kgamma are largely protected from imiquimod (IMQ)-induced psoriasis-like dermatitis, correlating with reduced IL-17 levels in the lesions, serum, and the draining lymph nodes. Imiquimod 88-97 interleukin 17A Mus musculus 164-169 23024273-3 2012 We found that mice lacking functional PI3Kdelta or PI3Kgamma are largely protected from imiquimod (IMQ)-induced psoriasis-like dermatitis, correlating with reduced IL-17 levels in the lesions, serum, and the draining lymph nodes. Imiquimod 99-102 interleukin 17A Mus musculus 164-169 23024273-4 2012 TCRgammadelta T cells were the major IL-17-producing population in the draining lymph nodes and were significantly diminished in IMQ-treated PI3Kdelta knockin and PI3Kgamma knockout mice. Imiquimod 129-132 interleukin 17A Mus musculus 37-42 23024273-6 2012 In addition, inhibition of PI3Kgamma, but not PI3Kdelta, blocked chemotaxis of CCR6(+)IL-17-producing cells from IMQ-treated mice or healthy human donors. Imiquimod 113-116 interleukin 17A Mus musculus 86-91 22431065-7 2013 Topical IMQ treatment induced T cell and plasmacytoid dendritic cell infiltrates at the tumor sites, where levels of IL-12/23p40, IL-12p35, IL-23p19, IL-17A, and IFN-gamma mRNAs were up-regulated. Imiquimod 8-11 interleukin 17A Mus musculus 150-156 23825622-4 2013 Here, we report that topical use of a curcumin gel formulation strongly inhibited imiquimod (IMQ)-induced psoriasis-like inflammation, the development of which was based on the IL-23/IL-17A axis. Imiquimod 82-91 interleukin 17A Mus musculus 183-189 23825622-4 2013 Here, we report that topical use of a curcumin gel formulation strongly inhibited imiquimod (IMQ)-induced psoriasis-like inflammation, the development of which was based on the IL-23/IL-17A axis. Imiquimod 93-96 interleukin 17A Mus musculus 183-189 34548208-6 2021 RESULTS: Apremilast alleviated IMQ-induced psoriasiform dermatitis clinically and pathologically on days 3-6 by reducing infiltration of antigen-presenting cells and interleukin (IL)-17A-positive cells and increasing infiltration of Foxp3-postive cells into the skin on day 6, although a significant increase in IL-10 mRNA level was not observed on day 2. Imiquimod 31-34 interleukin 17A Mus musculus 166-186 34780714-5 2022 Although mRNA levels of inflammatory cytokines in skin after topical application of 12-O-tetradecanoylphorbol-13-acetate or imiquimod were comparable between kCYC+/- and wild-type mice, protein levels of inflammatory cytokines such as interleukin (IL)-17A, IL-22, and IL-23 were significantly upregulated in kCYC+/- mice in both models. Imiquimod 124-133 interleukin 17A Mus musculus 235-255 34723528-5 2021 In animal studies, oral administration of compound d3 showed a robust and dose-dependent inhibition of the IL-17A cytokine expression in a mouse imiquimod-induced skin inflammation model. Imiquimod 145-154 interleukin 17A Mus musculus 107-113 19380832-3 2009 We hypothesized that IMQ-induced dermatitis in mice can serve as a model for the analysis of pathogenic mechanisms in psoriasis-like dermatitis and assessed its IL-23/IL-17 axis dependency. Imiquimod 21-24 interleukin 17A Mus musculus 167-172 19380832-6 2009 IMQ induced epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increase in splenic Th17 cells. Imiquimod 0-3 interleukin 17A Mus musculus 43-49 19380832-7 2009 IMQ-induced dermatitis was partially dependent on the presence of T cells, whereas disease development was almost completely blocked in mice deficient for IL-23 or the IL-17 receptor, demonstrating a pivotal role of the IL-23/IL-17 axis. Imiquimod 0-3 interleukin 17A Mus musculus 226-231 34364883-9 2022 Gene expression analysis identified upregulation of Mxa, Il1b, Tnfa, Il6, Il12, Il23, Il17 and Ifng in TG>WT>KO following IMQ treatment. Imiquimod 122-125 interleukin 17A Mus musculus 86-90 34328106-9 2021 The results showed that capsaicin administration obstructed the activation of IL-23/IL-17 pathway induced by imiquimod, presenting with significantly reduced psoriasiform dermatitis both in gross appearance and microscopic features. Imiquimod 109-118 interleukin 17A Mus musculus 84-89 34243099-0 2021 Tuhuaiyin alleviates imiquimod-induced psoriasis via inhibiting the properties of IL-17-producing cells and remodels the gut microbiota. Imiquimod 21-30 interleukin 17A Mus musculus 82-87 34153674-10 2021 Serum myeloperoxidase, IgG2a, IL-1beta, IL-6, IL-17, and TNF-alpha and spleen CD4+IFN-gamma+IL-17+ T lymphocytes were reduced after PD1 treatment in IMQ-induced psoriasiform mouse models. Imiquimod 149-152 interleukin 17A Mus musculus 46-51 34153674-10 2021 Serum myeloperoxidase, IgG2a, IL-1beta, IL-6, IL-17, and TNF-alpha and spleen CD4+IFN-gamma+IL-17+ T lymphocytes were reduced after PD1 treatment in IMQ-induced psoriasiform mouse models. Imiquimod 149-152 interleukin 17A Mus musculus 92-97 35253588-11 2022 Furthermore, asiatic acid (high-dose) suppressed the imiquimod-induced increase in serum levels of IL-17A and IL-23.Conclusion: These results indicate that asiatic acid showed an anti-psoriatic effect in the imiquimod-induced psoriasis model via mediating IL-17A and IL-23 pathways. Imiquimod 53-62 interleukin 17A Mus musculus 99-105 34171426-8 2021 Importantly, compared to MTX oral administration, topical application of MTX/NIC cerosomes on imiquimod (IMQ)-induced psoriatic mouse model exhibited a superior performance in ameliorating skin lesions, reducing spleen index and epidermal thickness, and downregulating the mRNA expression levels of proinflammatory cytokines including TNFalpha, IL-23, IL-17A, IL-6, IL-1beta, and IL-22. Imiquimod 105-108 interleukin 17A Mus musculus 352-358 34281197-9 2021 In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01. Imiquimod 123-126 interleukin 17A Mus musculus 38-44 34281197-9 2021 In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01. Imiquimod 172-175 interleukin 17A Mus musculus 38-44 35562873-6 2022 Imiquimod-induced psoriasis-like skin lesions, which present as erythematous papules and plaques with silver scaling, as well as markedly elevated IL-17/IL-23 cytokine levels in skin tissues, were significantly suppressed by Compound A in FFA4 WT mice, but not in FFA4 KO mice. Imiquimod 0-9 interleukin 17A Mus musculus 147-152 35562873-7 2022 Enlarged lymph nodes and spleens, as well as imiquimod-induced, elevated IL-17/IL-23 cytokine levels, were also strongly suppressed by Compound A in FFA4 WT mice, but not in FFA4 KO mice. Imiquimod 45-54 interleukin 17A Mus musculus 73-78 35562873-8 2022 Imiquimod-induced increases in the CD4+IL-17A+ T cell population in lymph nodes and spleens were suppressed by Compound A treatment in FFA4 WT mice; however, this was not seen in FFA4 KO mice. Imiquimod 0-9 interleukin 17A Mus musculus 39-45 35464441-6 2022 Consequently, TET nanoemulsion potently inhibited IL-17-expressing cells in the spleen and lymph nodes of imiquimod-treated WT mice, accompanied by decreased serum levels of IL-17A, INF-gamma, and TNF and their mRNA levels in the flamed lesion. Imiquimod 106-115 interleukin 17A Mus musculus 50-55 35464441-6 2022 Consequently, TET nanoemulsion potently inhibited IL-17-expressing cells in the spleen and lymph nodes of imiquimod-treated WT mice, accompanied by decreased serum levels of IL-17A, INF-gamma, and TNF and their mRNA levels in the flamed lesion. Imiquimod 106-115 interleukin 17A Mus musculus 174-180 34025642-9 2021 Hyperforin also suppressed the typical psoriasis-like inflammatory responses and the infiltration of IL-17A+ cells in dermal gammadelta T cells of IMQ treated Tcrd -/- mice transferred with gammadelta T cells. Imiquimod 147-150 interleukin 17A Mus musculus 101-107 34028144-4 2021 IMQ induced psoriatic symptoms such as erythema and scaling and also upregulated interleukin (IL)-17, a key effector cytokine of psoriasis, in the skin. Imiquimod 0-3 interleukin 17A Mus musculus 81-100 34025642-11 2021 In conclusion, hyperforin alleviates IMQ-induced inflammation in psoriasis through suppressing the immune responses exerted by IL-17 A-producing gammadelta T cells and related cytokines by modulating MAPK/STAT3 pathways. Imiquimod 37-40 interleukin 17A Mus musculus 127-134 33888401-12 2021 CONCLUSION: Our results demonstrated that fingolimod showed effectiveness for IMQ-induced psoriasiform dermatitis by hindering the emigration of IL-17A-producing gammadelta T cells from the lymph nodes to the skin, and suggest that fingolimod is a promising candidate for the treatment of psoriasis. Imiquimod 78-81 interleukin 17A Mus musculus 145-151 32584352-8 2020 STAT3-dependent IL-22 signalling and effects in keratinocytes are negatively regulated by the 310 nm UV-LED, which significantly ameliorated IMQ-induced psoriasis-like dermatitis development and reduced Th17 cytokine levels (IL-17A, IL-22) in serum and dorsal skin. Imiquimod 141-144 interleukin 17A Mus musculus 225-231 33836731-8 2021 CONCLUSION: Our study suggests that the anti-inflammatory effects of MabE on the activation of the macrophage cell line RAW246.7 by TLRs and IMQ-induced ear edema are through the inhibition of NF-kappaB activation and IL-17A-producing gammadeltaT cells, respectively. Imiquimod 141-144 interleukin 17A Mus musculus 218-224 32557852-0 2020 C5a/C5aR1 mediates IMQ-induced psoriasiform skin inflammation by promoting IL-17A production from gammadelta-T cells. Imiquimod 19-22 interleukin 17A Mus musculus 75-81 32752186-9 2020 These results suggest that IDO2 might decrease IL-17 expression, thereby resulting in the suppression of skin inflammation in IMQ-induced psoriasis-like dermatitis. Imiquimod 126-129 interleukin 17A Mus musculus 47-52 33643287-6 2020 We now confirm that induction of S100-alarmins in an imiquimod-induced murine model of psoriasis-like skin inflammation was associated with an increased expression of interleukin (IL)-1alpha, IL-6, IL-17A, or TNFalpha. Imiquimod 53-62 interleukin 17A Mus musculus 198-204 33509093-0 2021 Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist. Imiquimod 15-24 interleukin 17A Mus musculus 70-85 33509093-5 2021 Meanwhile, we validated the detailed involvement of IL17A signaling in disease progression, confirmed that the expression levels of IL17A and its related cytokines were induced by IMQ application, and its downstream cytokines can be inhibited by IL17A antagonist treatment. Imiquimod 180-183 interleukin 17A Mus musculus 52-57 33509093-5 2021 Meanwhile, we validated the detailed involvement of IL17A signaling in disease progression, confirmed that the expression levels of IL17A and its related cytokines were induced by IMQ application, and its downstream cytokines can be inhibited by IL17A antagonist treatment. Imiquimod 180-183 interleukin 17A Mus musculus 132-137 33509093-5 2021 Meanwhile, we validated the detailed involvement of IL17A signaling in disease progression, confirmed that the expression levels of IL17A and its related cytokines were induced by IMQ application, and its downstream cytokines can be inhibited by IL17A antagonist treatment. Imiquimod 180-183 interleukin 17A Mus musculus 132-137 33509093-6 2021 In further study, we revealed that IL17A was transient induced by IMQ and directly caused downstream signaling activation. Imiquimod 66-69 interleukin 17A Mus musculus 35-40 33509093-8 2021 CONCLUSIONS: Our work presents the application of a convenient psoriatic animal model in the research and development of IL17A antagonists, meanwhile providing extra evidence for understanding IL17A"s role in the progression of IMQ-induced psoriasis model, which manifest the research and development of IL17A antagonists. Imiquimod 228-231 interleukin 17A Mus musculus 121-126 33509093-8 2021 CONCLUSIONS: Our work presents the application of a convenient psoriatic animal model in the research and development of IL17A antagonists, meanwhile providing extra evidence for understanding IL17A"s role in the progression of IMQ-induced psoriasis model, which manifest the research and development of IL17A antagonists. Imiquimod 228-231 interleukin 17A Mus musculus 193-198 33509093-8 2021 CONCLUSIONS: Our work presents the application of a convenient psoriatic animal model in the research and development of IL17A antagonists, meanwhile providing extra evidence for understanding IL17A"s role in the progression of IMQ-induced psoriasis model, which manifest the research and development of IL17A antagonists. Imiquimod 228-231 interleukin 17A Mus musculus 193-198 33450859-6 2021 Nevertheless, topically applied MSC exosomes in a mouse model of imiquimod (IMQ) psoriasis significantly reduced IL-17 and terminal complement activation complex C5b-9 in the mouse skin. Imiquimod 65-74 interleukin 17A Mus musculus 113-118 33450859-6 2021 Nevertheless, topically applied MSC exosomes in a mouse model of imiquimod (IMQ) psoriasis significantly reduced IL-17 and terminal complement activation complex C5b-9 in the mouse skin. Imiquimod 76-79 interleukin 17A Mus musculus 113-118 33171607-6 2020 Topical application of HWG-35D ameliorated IMQ-induced skin lesions and normalized the serum interleukin-17A levels elevated by IMQ. Imiquimod 128-131 interleukin 17A Mus musculus 93-108 33081840-20 2020 Daphnetin treatment attenuated IMQ-induced upregulation of inflammatory cytokines including IL-6, IL-23A and IL-17A in skin lesion of mice. Imiquimod 31-34 interleukin 17A Mus musculus 109-115 33205009-6 2020 In contrast, imiquimod broadly upregulates Il17/Il22 and Ccl4/Ccl5. Imiquimod 13-22 interleukin 17A Mus musculus 43-47